Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 26Unknown 8Recruiting 8Terminated 4Active not recruiting 3Withdrawn 1No longer available 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 57Leukemia, Myeloid, Acute 53Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Myeloproliferative Disorders 24Leukemia 24Primary Myelofibrosis 22Leukemia, Myelomonocytic, Chronic 19Lymphoma, Non-Hodgkin 18Leukemia, Lymphocytic, Chronic, B-Cell 18Hodgkin Disease 16Lymphoma, Follicular 15Multiple Myeloma 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell, Marginal Zone 14Leukemia, Myeloid, Chronic-Phase 14Burkitt Lymphoma 14Polycythemia Vera 13Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Leukemia, Myeloid, Accelerated Phase 12Lymphoma, Large-Cell, Immunoblastic 11Hematologic Neoplasms 11Congenital Abnormalities 11Blast Crisis 11Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 10Sezary Syndrome 9Recurrence 9Pdgfra-Associated Chronic Eosinophilic Leukemia 9Mycosis Fungoides 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Mastocytosis, Systemic × Myeloid × Clear all
NCT03739606 2020-12-17

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

City of Hope Medical Center

Phase 2 Withdrawn
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡